Research Outlook with Prof Gareth Evans
09 April 2019
Research Outlook with Prof Gareth Evans
Prof Gareth Evans is the Chair of the Medical Advisory Board of Nerve Tumours UK, and has an established international reputation in the treatment and research of Neurofibromatosis. Here he gives a brief overview of the current research landscape for NF.
There is very little funded research in the UK – the research in the UK which is published is rarely fully funded. We are reliant for the most part on developments in the US, which is underpinned by around $15m a year in grants from the US Department of Defense.
The most hopeful developments are in drug treatments, MEK Inhibitors for NF1, and Avastin for NF2 (each described below). I am hopeful that these drug treatments will become mainstays in UK treatment.
NF2: Avastin
Extract from Addenbrooke’s Hospital, Cambridge:
Avastin is a type of drug treatment known as antiangiogenic therapy. It works by blocking signals made by tumours that cause blood vessels to grow in their vicinity. Without the
support of blood vessels, the tumour lacks nutrients and oxygen needed to grow. The NHS national programme for Avastin therapy for NF2 patients has been running since 2010. The
latest evaluation shows that in 90% of patients the tumour either shrinks or stops growing and hearing function either stabilises or improves in 86% of patients.
Extract from Oxford University Hospitals’ information guide:
Avastin is given to people with NF2 when a schwannoma has grown by a specific amount or more over the previous year. The schwannoma will be measured by looking at and comparing
MRI scans over the course of a year. Evidence suggests that Avastin is more effective in faster growing tumours. National guidelines state that patients need to have schwannomas that meet the specific growth rate criteria for them to be considered for treatment with Avastin.
Avastin is given for the treatment of NF2 initially for six months, with three monthly MRI scans and clinic reviews. If a tumour starts to grow despite having Avastin treatment, then the drug will be stopped. The drug will also be stopped if you suffer significant side effects.
– Prof Gareth Evans"The latest evaluation shows that in 90% of patients the tumour either shrinks or stops growing"
NF1: MEK Inhibitors
Neurofibromin is the protein which is downstream of the NF1 gene, and suppresses the proliferation of
tumours. It is its absence that causes tumours for people with NF1. The way that MEK Inhibitors work has been helpfully described by Dr Annette Bakker, President and Chief Scientific Officer of the Children’s Tumor Foundation, in the US. She uses the analogy of an unruly classroom, where neurofibromin is the teacher who normally keeps control, but is absent. MEK is the naughtiest child in the class, who causes most of the trouble in the absence of the teacher. The MEK Inhibitor drug keeps that naughty child under control.
A study by French researchers reported in ecancermedicalscience, showed dramatic results in a 12-year-old boy with NF1, who was finding walking impossible, and suffering increased pain in his hand (see images on the right). Within a week of beginning treatment with a MEK Inhibitor, Trametinib, he was walking again, and the pain had disappeared. These results were sustained, and after a year, he no longer needed to take the drug.
MEK Inhibitors are currently undergoing clinical trials in the US, and are showing similarly ‘spectacular’ results. The Children’s Tumor Foundation are hopeful they will soon be approved
for patient treatment.
– Prof Gareth Evans"Within a week of beginning treatment with a MEK Inhibitor, Trametinib, he was walking again, and the pain had disappeared."
Filter News
Looking Back, Moving Forward: A Message from Our Charity Director
Read MoreOliver’s Blog
Oliver Bromley shares some personal experiences of visible difference, and how education and kindness can reduce stigma
Read MoreEllen’s Story
Read Ellen's story, how she recovered from 'radical surgery' and why she's raising funds for NTUK.
Read MoreCelebrating Trustees Week
It's National Trustee Week: Meet the people who keep NTUK moving.
Read MoreMen’s Health Month
We're making sure that men with NF are prioritising their health, both in and out of the workplace.
Read MoreIrfan’s Story
Irfan discusses his NF journey, how he transformed uncertainty and isolation into community and understanding.
Read MoreKelly’s Story
Find out how Kelly discovered her confidence after overcoming testing years at school and college.
Read MoreAwareness Walks
Raise awareness with an organised walk within your community. We've put together some pointers to help you with planning.
Read MoreMeena’s Awareness Raising Coastal Walk
NTUK trustee Prof. Meena Upadhyaya treks the Welsh coast to raise awareness of NF and rare diseases.
Read More